RecruitingNCT07636252
EX VIVO DRUG RESPONSE PROFILING AND OUTCOME PREDICTION IN LUNG ADENOCARCINOMA
Sponsor
Sheba Medical Center
Enrollment
400 participants
Start Date
Jun 14, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
- Patient's written informed consent present.
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Exclusion Criteria1
- negative cytology for malignancy in the last 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-Interventional Study, patients go through pleural drainage due to shortness of breath
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07636252
Related Trials
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
NCT0519883034 locations
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
NCT076336261 location
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT0579716860 locations
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT068436291 location
First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
NCT073328581 location